| Yasir Al-abboodi, MD | |
|
6818 Austin Center Blvd Ste 205, Austin, TX 78731-3100 | |
| (512) 344-0450 | |
| (512) 406-7318 |
| Full Name | Yasir Al-abboodi |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 19 Years |
| Location | 6818 Austin Center Blvd Ste 205, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295095081 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | Q9775 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Hills Surgical Hospital | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Regional Clinic Pa | 3072507789 | 349 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Entity Name | Austin Regional Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821157579 PECOS PAC ID: 3072507789 Enrollment ID: O20040414000198 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Entity Name | Cogent Healthcare Of Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992722953 PECOS PAC ID: 8628076924 Enrollment ID: O20061121000364 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Entity Name | Sound Inpatient Physicians Of Texas I, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831424563 PECOS PAC ID: 8729133640 Enrollment ID: O20090828000300 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Entity Name | Lonestar Hospital Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518237429 PECOS PAC ID: 6709049703 Enrollment ID: O20120530000620 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yasir Al-abboodi, MD 6210 E Hwy 290 Ste 240, Austin, TX 78723-1144 Ph: (512) 483-9596 | Yasir Al-abboodi, MD 6818 Austin Center Blvd Ste 205, Austin, TX 78731-3100 Ph: (512) 344-0450 |
News Archive
Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research.
Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
A new American study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, calls for more aggressive management of osteoporosis in the extreme elderly as the true impact of osteoporotic hip fractures in those aged 80 years or older is unveiled.
After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.
› Verified 3 days ago
Dr. Tatiana B. Jacobson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd. Bldg C Ste. 102, Austin, TX 78746 Phone: 512-323-5465 Fax: 512-327-1390 | |
Preeti Venkatraman, M.B.B.S. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-7000 | |
Pritesh Harish Gandhi, M.D., M.P.H. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1101 Camino La Costa, Austin, TX 78752 Phone: 512-684-1832 | |
Dr. Joshua Lane Davis, D.O. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1004 W 32nd St Unit 300, Austin, TX 78705 Phone: 512-324-3440 | |
Dr. Analicia Alvarado, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-324-7000 | |
Dr. Grace Marie Grant-jennings, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Dr. Debra Ann Patt, MD, MPH Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6204 Balcones Dr, Austin, TX 78731 Phone: 512-427-9400 Fax: 512-342-2723 |